Semaglutide, the GLP-1 drug that Novo sells under the brand names Ozempic for diabetes and Wegovy for weight loss, has made ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

The odds for aspiration is greatest in the first weeks after a GLP-1 med is prescribed, since the delay in stomach emptying ...

Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) prior to bariatric surgery was safe but wasn’t associated with ...

Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...

A mixed sales report for Novo Nordisk’s GLP-1 megablockbuster drugs failed to quiet concerns Wednesday that investors may ...

A new Northbrook pharma will work to bring its obesity treatment to market that it says holds advantages over Ozempic and its ...

GLP-1 drugs help manage diabetes and promote weight loss by mimicking the GLP-1 hormone, which works to control insulin and ...

GLP-1 receptor agonists, originally developed for managing type ... By reducing hunger and promoting a feeling of fullness, ...

Maryland’s policymakers should expand Medicaid coverage to include weight loss medications, writes Michelle Rogers.